This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Aug. 8, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of biologics focused on the prevention and treatment of serious infectious diseases, announced today that it intends to release its financial results for the second quarter ended
June 30, 2013 on
Wednesday, August 14, 2013.
The Company will hold an investor conference call on
Wednesday, August 14, 2013, at
4:00 pm EDT. During the call,
Jeffrey Riley, Synthetic Biologics' Chief Executive Officer, will provide a brief update of the Company's multiple sclerosis program and its infectious disease pipeline, including its oral enzyme candidate for the prevention of
C. difficile infections and monoclonal antibody candidates for the treatment of Pertussis and
C. Evan Ballantyne, Synthetic Biologics' Chief Financial Officer, will review the Company's financial results for the second quarter ended
June 30, 2013.
Interested parties should call 1-800-860-2442 (U.S. toll free), 1-866-605-3852 (
Canada), or +1 412-858-4600 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at
http://www.videonewswire.com/event.asp?id=95523. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL,
http://www.videonewswire.com/event.asp?id=95523 for 30 days after the call.
About Synthetic Biologics, Inc.
Synthetic Biologics, Inc. (NYSE MKT: SYN) is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of
C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and
Acinetobacter infections. In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis. For more information, please visit Synthetic Biologics' website at
To download Synthetic Biologics' investor relations mobile device app, which allows users access to the Company's SEC documents, press releases and events, please click on the following links to download the IRapp on your
iPhone and iPad or your
Android mobile device.
SOURCE Synthetic Biologics, Inc.